Inhibiteurs des tyrosine kinases et diabète

Tyrosine kinase inhibitors (TKIs) are targeted therapies which are widely used in clinical oncology. TKIs target common mechanisms of growth, invasion, metastasis, and angiogenesis. However, many TKIs are nonselective and their use is associated with important side effects, especially endocrine-related side effects. Consistent data indicate that TKIs influence glucose metabolism. Surprisingly, both increased and decreased plasma glucose levels have been attributed to TKIs. Thus, it is actually recommended to monitor HbA1c and blood glucose levels periodically in patients treated with TKIs.